TADALAFIL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H19N3O4
Molecular Weight	389.4048
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1CC(=O)N2[C@]([H])(Cc3c4ccccc4[nH]c3[C@@]2([H])c5ccc6c(c5)OCO6)C1=O

InChI

InChIKey=WOXKDUGGOYFFRN-IIBYNOLFSA-N

InChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB00820
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021368s20s21lbl.pdf

Tadalafil is used to treat male erectile dysfunction (impotence) and pulmonary arterial hypertension (PAH). Part of the physiological process of erection involves the release of nitric oxide (NO) in the corpus cavernosum. This then activates the enzyme guanylate cyclase which results in increased levels of cyclic guanosine monophosphate (cGMP), leading to smooth muscle relaxation in the corpus cavernosum, resulting in increased inflow of blood and an erection. Tadalafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum. This means that, with tadalafil on board, normal sexual stimulation leads to increased levels of cGMP in the corpus cavernosum which leads to better erections. Without sexual stimulation and no activation of the NO/cGMP system, tadalafil should not cause an erection.Tadalafil inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by tadalafil enhances erectile function by increasing the amount of cGMP. Tadalafil is used for the treatment of erectile dysfunction.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
HERG 89 Target ID: CHEMBL240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27581752	Inhibitor 7728	100.0 µM [IC50]
Phosphodiesterase 6 2 Target ID: CHEMBL2097163 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24180640	Inhibitor 7728	5.1 µM [IC50]
Phosphodiesterase 11A 3 Target ID: CHEMBL2717 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21384413	Inhibitor 7728	0.05 µM [IC50]
Phosphodiesterase 5A 30 Target ID: CHEMBL1827 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021368s20s21lbl.pdf	Inhibitor 7728	5.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Benign prostatic hyperplasia 28 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021368s20s21lbl.pdf	Primary		Approved 8043	CIALIS Approved Use CIALIS® is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of: • erectile dysfunction (ED) • the signs and symptoms of benign prostatic hyperplasia (BPH) • ED and the signs and symptoms of BPH (ED/BPH) Launch Date 1.06928642E12
Erectile dysfunction 33 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021368s20s21lbl.pdf	Primary		Approved 8043	CIALIS Approved Use CIALIS® is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of: • erectile dysfunction (ED) • the signs and symptoms of benign prostatic hyperplasia (BPH) • ED and the signs and symptoms of BPH (ED/BPH) Launch Date 1.06928642E12

C_max

Value	Dose	Co-administered	Analyte	Population
308.1 μg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29719379	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		TADALAFIL blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
7225 μg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29719379	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		TADALAFIL blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
17.4 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29719379	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		TADALAFIL blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
6% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022332lbl.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		TADALAFIL unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
40 mg 1 times / day multiple, oral MTD Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31131648	pregnant, 28 years (range: 20–39 years) n = 3 Health Status: pregnant Age Group: 28 years (range: 20–39 years) Sex: F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/31131648	Other AEs: Facial flushing, Anorexia... Other AEs: Facial flushing (grade 1, 2 patients) Anorexia (grade 1, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/31131648
20 mg 3 times / week multiple, oral Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/15925082/	unhealthy, 54.9 years n = 4262 Health Status: unhealthy Condition: Erectile Dysfunction Age Group: 54.9 years Sex: M Population Size: 4262 Sources: https://pubmed.ncbi.nlm.nih.gov/15925082/	Other AEs: Headache, Dyspepsia... Other AEs: Headache (7.7%) Dyspepsia (7%) Back pain (2.9%) Flushing (2.9%) Myalgia (3%) Abdominal pain upper (1.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/15925082/
100 mg 1 times / day multiple, oral Highest studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022332lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: erectile dysfunction Age Group: adult Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022332lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022332lbl.pdf
500 mg single, oral Highest studied dose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022332lbl.pdf	healthy, adult Health Status: healthy Age Group: adult Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022332lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022332lbl.pdf

AEs

AE	Significance	Dose	Population
Anorexia	grade 1, 1 patient	40 mg 1 times / day multiple, oral MTD Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31131648	pregnant, 28 years (range: 20–39 years) n = 3 Health Status: pregnant Age Group: 28 years (range: 20–39 years) Sex: F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/31131648
Facial flushing	grade 1, 2 patients	40 mg 1 times / day multiple, oral MTD Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31131648	pregnant, 28 years (range: 20–39 years) n = 3 Health Status: pregnant Age Group: 28 years (range: 20–39 years) Sex: F Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/31131648
Abdominal pain upper	1.7%	20 mg 3 times / week multiple, oral Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/15925082/	unhealthy, 54.9 years n = 4262 Health Status: unhealthy Condition: Erectile Dysfunction Age Group: 54.9 years Sex: M Population Size: 4262 Sources: https://pubmed.ncbi.nlm.nih.gov/15925082/
Back pain	2.9%	20 mg 3 times / week multiple, oral Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/15925082/	unhealthy, 54.9 years n = 4262 Health Status: unhealthy Condition: Erectile Dysfunction Age Group: 54.9 years Sex: M Population Size: 4262 Sources: https://pubmed.ncbi.nlm.nih.gov/15925082/
Flushing	2.9%	20 mg 3 times / week multiple, oral Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/15925082/	unhealthy, 54.9 years n = 4262 Health Status: unhealthy Condition: Erectile Dysfunction Age Group: 54.9 years Sex: M Population Size: 4262 Sources: https://pubmed.ncbi.nlm.nih.gov/15925082/
Myalgia	3%	20 mg 3 times / week multiple, oral Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/15925082/	unhealthy, 54.9 years n = 4262 Health Status: unhealthy Condition: Erectile Dysfunction Age Group: 54.9 years Sex: M Population Size: 4262 Sources: https://pubmed.ncbi.nlm.nih.gov/15925082/
Dyspepsia	7%	20 mg 3 times / week multiple, oral Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/15925082/	unhealthy, 54.9 years n = 4262 Health Status: unhealthy Condition: Erectile Dysfunction Age Group: 54.9 years Sex: M Population Size: 4262 Sources: https://pubmed.ncbi.nlm.nih.gov/15925082/
Headache	7.7%	20 mg 3 times / week multiple, oral Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/15925082/	unhealthy, 54.9 years n = 4262 Health Status: unhealthy Condition: Erectile Dysfunction Age Group: 54.9 years Sex: M Population Size: 4262 Sources: https://pubmed.ncbi.nlm.nih.gov/15925082/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1601 inhibitor 1467 inducer 707	inhibitor 1604 inducer 355	inhibitor 1702 inducer 97	inhibitor 1475

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1383 CYP2C19 1325 CYP2E1 790	P-gp 1400	CYP1A2 637 CYP2C19 269 CYP2E1 117

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP2C19 1392	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021368lbl.pdf#page=14 Page: 14.0	no
CYP2D6 1738	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021368lbl.pdf#page=14 Page: 14.0	no
CYP2D6 1738	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021368lbl.pdf#page=14 Page: 14.0	no
CYP2E1 871	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021368lbl.pdf#page=14 Page: 14.0	no
CYP2E1 871	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021368lbl.pdf#page=14 Page: 14.0	no
CYP1A2 1532	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021368lbl.pdf#page=14 Page: 14.0	no	no (co-administration study) Comment: taladafil had no clinically significant effect on PK of theophylline Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021368lbl.pdf#page=14 Page: 14.0
CYP1A2 1532	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021368lbl.pdf#page=14 Page: 14.0	no	no (co-administration study) Comment: taladafil had no clinically significant effect on PK of theophylline Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021368lbl.pdf#page=14 Page: 14.0
CYP2C9 1648	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021368lbl.pdf#page=14 Page: 14.0	no	no (co-administration study) Comment: Tadalafil had no clinically significant effect on exposure (AUC) to S-warfarin or R-warfarin, nor did tadalafil affect changes in prothrombin time induced by warfarin. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021368lbl.pdf#page=14 Page: 14.0
CYP2C9 1648	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021368lbl.pdf#page=14 Page: 14.0	no	no (co-administration study) Comment: Tadalafil had no clinically significant effect on exposure (AUC) to S-warfarin or R-warfarin, nor did tadalafil affect changes in prothrombin time induced by warfarin. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021368lbl.pdf#page=14 Page: 14.0
CYP3A4 1772	inducer 1440 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021368lbl.pdf#page=14 Page: 14.0	no	no (co-administration study) Comment: taladafil had no clinically significant effect on exposure (AUC) to midazolam or lovastatin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021368lbl.pdf#page=14 Page: 14.0
CYP3A4 1772	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021368lbl.pdf#page=14 Page: 14.0	no	no (co-administration study) Comment: taladafil had no clinically significant effect on exposure (AUC) to midazolam or lovastatin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021368lbl.pdf#page=14 Page: 14.0
CYP2C19 1392	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-368_Cialis_BioPharmr_P2.pdf#page=40 Page: 40.0	not significant [Ki 73 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1601	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-368_Cialis_BioPharmr_P2.pdf#page=49 Page: 49.0	major		yes (co-administration study) Comment: coadministration with ketoconazole (inhibitor) increased tadalafil exposure by 107%; ritonavir (inhibitor) increased tadalafil AUC by 124%; coadministration with rifampin (inducer) reduced taladafil AUC by 88%; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-368_Cialis_BioPharmr_P2.pdf#page=49 Page: 49.0
P-gp 1400	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/28769012/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1507	inhibitor 1489 Sources: https://europepmc.org/article/med/15476742

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:71940	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:71940
ChemicalBook	CB2236841	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2236841
MolPort	MolPort-002-885-864	https://www.molport.com/shop/molecule-link/MolPort-002-885-864
Selleck Chemicals	Tadalafil(Cialis)	http://www.selleckchem.com/products/Tadalafil(Cialis).html
ZINC	ZINC000003993855	http://zinc15.docking.org/substances/ZINC000003993855
eMolecules	29781353	https://www.emolecules.com/cgi-bin/more?vid=29781353
eMolecules	33507691	https://www.emolecules.com/cgi-bin/more?vid=33507691
eMolecules	36754634	https://www.emolecules.com/cgi-bin/more?vid=36754634

PubMed

Title	Date	PubMed
Effects of tadalafil on erectile dysfunction in men with diabetes.	2003 Aug	14601573
Tadalafil: new preparation. Slightly more convenient, but poorly assessed in organic disorders.	2003 Dec	14986690
Oral drug treatment of erectile dysfunction.	2003 Dec	14695970
Tadalafil in the treatment of erectile dysfunction.	2003 Dec	14622501
Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists.	2003 Dec	14622499
Tadalafil for the treatment of erectile dysfunction.	2003 Dec	14622498
Tadalafil (cialis) for erectile dysfunction.	2003 Dec 22	14679352
Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference.	2003 Nov	14693300
A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction.	2003 Nov	14693299
Review of tadalafil in the treatment of erectile dysfunction.	2003 Nov	14596658
[Pleasure and pain in sexual relations. The basis and reasons for sex counseling by the general practitioner].	2003 Nov 13	14699831
Time course of the interaction between tadalafil and nitrates.	2003 Nov 19	14642699
Roundtable discussion: tadalafil study group.	2003 Nov 6	14609624
Cardiovascular effects of tadalafil in patients on common antihypertensive therapies.	2003 Nov 6	14609623
Cardiovascular effects of tadalafil.	2003 Nov 6	14609622
Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction.	2003 Nov 6	14609620
Overview of phosphodiesterase 5 inhibition in erectile dysfunction.	2003 Nov 6	14609619
[Efficacy and safety of the application of cialis for erectile dysfunction].	2003 Nov-Dec	14708250
Novel PDE5 inhibitors for the treatment of male erectile dysfunction.	2003 Oct-Nov	14656408
[Medication of the month. Vardenafil (Levitra)].	2003 Sep	14626653
Sexual dysfunction and diabetes.	2004 Apr	15161120
[Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction].	2004 Apr	15148932
Gateways to clinical trials.	2004 Apr	15148527
Tadalafil and vardenafil.	2004 Apr	15124623
Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters.	2004 Apr	15115192
Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles.	2004 Apr	15115191
Pills for erectile dysfunction: now there are three.	2004 Apr	15100064
Treatment of erectile dysfunction.	2004 Apr	15075013
A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil.	2004 Apr	15041116
Tadalafil (Cialis) and vardenafil (Levitra) recently approved drugs for erectile dysfunction.	2004 Feb	15054911
[Erectile dysfunction. Epidemiology, physiology, etiology, diagnosis and therapy].	2004 Feb	14991124
Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.	2004 Feb	14871543
Cialis is here. The soft sell.	2004 Feb 2	14974376
[Treatment of erectile dysfunction].	2004 Feb 29	15077482
Are they better than Viagra? Two new drugs for erectile dysfunction work like Viagra and carry similar risks and benefits. Their subtle differences, however, may make a difference for some men.	2004 Jan	14734283
Third drug for impotence.	2004 Jan-Feb	15032184
[Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors].	2004 Jul	15197447
The efficacy and safety of tadalafil: an update.	2004 Jun	15180622
Re: tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones.	2004 Jun	15126856
Time course of the interaction between tadalafil and nitrates.	2004 Jun 2	15172433
Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors.	2004 Mar	15083994
Therapeutic options for patients returning to sexual activity.	2004 Mar	15083992
Gateways to clinical trials.	2004 Mar	15071612
Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction.	2004 Mar	15036680
Atazanavir (Reyataz): new recommendations if combined with tenofovir (Viread) -- and warning on Viagra, Cialis, and Levitra.	2004 Mar 26	15199867
Therapy of ED: PDE-5 Inhibitors.	2004 Mar-Apr	15146092
New drugs of 2003.	2004 Mar-Apr	15098851
Emerging oral drugs for erectile dysfunction.	2004 May	15155143
Nocturnal electrobioimpedance volumetric assessment in diabetic men with erectile dysfunction before and after tadalafil intake.	2004 Oct	15057255
Interactions between cGMP- and cAMP-pathways are involved in the regulation of penile smooth muscle tone.	2004 Oct	15045518

Patents

Sample Use Guides

In Vivo Use Guide

ED: Starting dose: 10 mg as needed prior to sexual activity. Increase to 20 mg or decrease to 5 mg based upon efficacy/tolerability. Improves erectile function compared to placebo up to 36 hours post dose. Not to be taken more than once per day

Route of Administration: Oral

In Vitro Use Guide

Increasing levels of tadalafil (1–25 uM) attenuated proliferation of human primary prostatic stromal cells (PrSCs) in a dose-dependent manner with concentrations above 5 uM showing highly significant effects

Name

Type

Language

TADALAFIL

Official Name

English

(6R,12AR)-2,3,6,7,12,12A-HEXAHYDRO-2-METHYL-6-(3,4-(METHYLENEDIOXY)PHENYL) PYRAZINO(1',2':1,6)PYRIDO(3,4-B)INDOLE-1,4-DIONE

Common Name

English

TADALAFIL [HSDB]

Common Name

English

TRANS-TADALAFIL

Common Name

English

TADALAFIL [WHO-DD]

Common Name

English

TADALAFIL [MART.]

Common Name

English

TADALAFIL [USP MONOGRAPH]

Common Name

English

TADALAFIL [JAN]

Common Name

English

PYRAZINO(1',2':1,6)PYRIDO(3,4-B)INDOLE-1,4-DIONE, 6-(1,3-BENZODIOXOL-5-YL)-2,3,6,7,12,12A-HEXAHYDRO-2-METHYL-, (6R-12AR)-

Common Name

English

CIALIS

Brand Name

English

TADALAFIL [MI]

Common Name

English

LY-450190

Code

English

TADALAFIL [EP MONOGRAPH]

Common Name

English

TADALAFIL [EMA EPAR]

Common Name

English

LY450190

Code

English

TADALAFIL [USP-RS]

Common Name

English

NSC-759172

Code

English

TADALAFIL MYLAN

Brand Name

English

TADALAFIL [USAN]

Common Name

English

TADALAFIL [INN]

Common Name

English

TADALAFIL [VANDF]

Common Name

English

NSC-750236

Code

English

(6R-TRANS)-6-(1,3-BENZODIOXOL-5-YL)-2,3,6,7,12,12A-HEXAHYDRO-2-METHYL-PYRAZINO(1',2':1,6)PYRIDO(3,4-B)INDOLE-1,4-DIONE

Common Name

English

IC351

Code

English

TADALAFIL [ORANGE BOOK]

Common Name

English

IC-351

Code

English

Classification Tree Code System Code

WHO-ATC

C02KX52